Published in Curr Pharm Des on January 01, 2011
All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease. Virulence (2011) 1.05
Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob Agents Chemother (2014) 1.05
Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J (2013) 1.01
Emerging trends in the discovery of natural product antibacterials. Curr Opin Pharmacol (2013) 0.97
Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes. Photochem Photobiol (2012) 0.94
Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Medchemcomm (2015) 0.82
Novel adjunctive therapies for the treatment of tuberculosis. Curr Mol Med (2014) 0.80
A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discov Today Technol (2014) 0.78
Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy. PLoS Biol (2016) 0.76
Hyperosmotic agents and antibiotics affect dissolved oxygen and pH concentration gradients in Staphylococcus aureus biofilms. Appl Environ Microbiol (2017) 0.75
Design of New Antibacterial Enhancers Based on AcrB's Structure and the Evaluation of Their Antibacterial Enhancement Activity. Int J Mol Sci (2016) 0.75
The Biofilm Inhibitor Carolacton Enters Gram-Negative Cells: Studies Using a TolC-Deficient Strain of Escherichia coli. mSphere (2017) 0.75
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (2009) 8.65
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science (2003) 7.96
Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature (2000) 7.30
A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature (2003) 6.06
Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev (2009) 5.76
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol (2006) 5.18
Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev (2006) 4.77
Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci (2004) 4.60
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res (1981) 4.30
The biology and future prospects of antivirulence therapies. Nat Rev Microbiol (2008) 3.83
Efflux-mediated antimicrobial resistance. J Antimicrob Chemother (2005) 3.69
ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer (2010) 3.44
Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother (1998) 3.26
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother (2002) 3.18
Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol (2002) 2.98
Structure of the multidrug transporter EmrD from Escherichia coli. Science (2006) 2.93
Structural evidence for induced fit and a mechanism for sugar/H+ symport in LacY. EMBO J (2006) 2.92
Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem (2004) 2.74
Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo) (2009) 2.71
Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci U S A (2000) 2.71
Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun (2003) 2.67
Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci U S A (2004) 2.66
The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc Natl Acad Sci U S A (2009) 2.47
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Bile salts and fatty acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. Mol Microbiol (2003) 2.18
Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. Biochem Pharmacol (2006) 2.14
The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist (2002) 2.09
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 2.04
Antibiotic efflux pumps. Biochem Pharmacol (2000) 1.99
Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep (2009) 1.97
Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2001) 1.96
Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother (2002) 1.96
Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun (1988) 1.88
Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol (2008) 1.88
Three's company: component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct Biol (2004) 1.84
Comparative analyses of fundamental differences in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput Biol (2005) 1.82
ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther (2005) 1.79
Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. J Bacteriol (2005) 1.78
On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol (2002) 1.77
Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. J Biol Chem (1993) 1.76
Crystal structures of the CusA efflux pump suggest methionine-mediated metal transport. Nature (2010) 1.76
High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother (2000) 1.75
Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol (2008) 1.75
Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.74
Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature (2010) 1.72
Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol (2009) 1.69
Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med (2005) 1.66
Crystal structures of multidrug binding protein TtgR in complex with antibiotics and plant antimicrobials. J Mol Biol (2007) 1.55
Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol (2001) 1.51
Crystal structure of the periplasmic component of a tripartite macrolide-specific efflux pump. J Mol Biol (2009) 1.50
Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.48
Prospects for plant-derived antibacterials. Nat Biotechnol (2006) 1.48
Reversal of fluconazole resistance by sulfated sterols from the marine sponge Topsentia sp. J Nat Prod (2009) 1.46
Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother (2007) 1.43
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother (2000) 1.37
Bacterial efflux systems and efflux pumps inhibitors. Biochimie (2005) 1.35
Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother (2004) 1.34
ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol Mol Biol Rev (2009) 1.34
Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter Bmr. J Bacteriol (1997) 1.33
Efflux in fungi: la pièce de résistance. PLoS Pathog (2009) 1.33
Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. J Antimicrob Chemother (1998) 1.32
A study of the uptake of toluidine blue O by Porphyromonas gingivalis and the mechanism of lethal photosensitization. Photochem Photobiol (1998) 1.32
Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol (2008) 1.32
Antifungal activity of anthraquinone derivatives from Rheum emodi. J Ethnopharmacol (2000) 1.32
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.31
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine. Antimicrob Agents Chemother (2008) 1.31
Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol (2004) 1.30
Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2005) 1.30
An isoflavonoid-inducible efflux pump in Agrobacterium tumefaciens is involved in competitive colonization of roots. J Bacteriol (1998) 1.27
The crystal structure of the outer membrane protein VceC from the bacterial pathogen Vibrio cholerae at 1.8 A resolution. J Biol Chem (2005) 1.27
Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother (2005) 1.26
Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem Biol (2006) 1.24
SMR-type multidrug resistance pumps. Curr Opin Drug Discov Devel (2001) 1.23
Multidrug efflux pump overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes. Microbiology (2008) 1.22
Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother (2006) 1.22
Multiresistance genes of Rhizobium etli CFN42. Mol Plant Microbe Interact (2000) 1.21
QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Antimicrob Agents Chemother (1998) 1.20
Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J Antimicrob Chemother (2006) 1.20
Phytochemicals for bacterial resistance--strengths, weaknesses and opportunities. Planta Med (2008) 1.20
The crystal structure of MexR from Pseudomonas aeruginosa in complex with its antirepressor ArmR. Proc Natl Acad Sci U S A (2008) 1.20
Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19
The Salmonella enterica sv. Typhimurium smvA, yddG and ompD (porin) genes are required for the efficient efflux of methyl viologen. Mol Microbiol (2002) 1.19
Eukaryotic major facilitator superfamily transporter modeling based on the prokaryotic GlpT crystal structure. Mol Membr Biol (2007) 1.18
Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov (2009) 1.15
High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol (2008) 1.14
In search of natural substrates and inhibitors of MDR pumps. J Mol Microbiol Biotechnol (2001) 1.13
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs (1997) 1.13
Role of the rapA gene in controlling antibiotic resistance of Escherichia coli biofilms. Antimicrob Agents Chemother (2007) 1.12
Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents (2003) 1.12
Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes strains. Biochem Biophys Res Commun (2002) 1.11
Two host-induced Ralstonia solanacearum genes, acrA and dinF, encode multidrug efflux pumps and contribute to bacterial wilt virulence. Appl Environ Microbiol (2007) 1.10
ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents (2003) 1.10
Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother (2008) 1.09
Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal Biochem (2009) 1.08
Killing of methicillin-resistant Staphylococcus aureus by low-power laser light. J Med Microbiol (1995) 1.08
A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 9.80
Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol (2006) 5.20
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol (2008) 3.20
G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res (2007) 2.71
In vivo effects of a GPR30 antagonist. Nat Chem Biol (2009) 2.39
Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol (2004) 2.36
A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol (2009) 2.29
Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol (2007) 2.20
Release of ubiquitin-charged Cdc34-S - Ub from the RING domain is essential for ubiquitination of the SCF(Cdc4)-bound substrate Sic1. Cell (2003) 1.94
Quantifying the relationships among drug classes. J Chem Inf Model (2008) 1.92
FRET detection of cellular alpha4-integrin conformational activation. Biophys J (2003) 1.88
Suspension array technology: evolution of the flat-array paradigm. Trends Biotechnol (2002) 1.81
Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg (2011) 1.68
BDDCS applied to over 900 drugs. AAPS J (2011) 1.68
An automated PLS search for biologically relevant QSAR descriptors. J Comput Aided Mol Des (2005) 1.66
Discovery of regulators of receptor internalization with high-throughput flow cytometry. Mol Pharmacol (2012) 1.61
GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol (2007) 1.59
ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle. Cell (2005) 1.55
Interactive exploration of chemical space with Scaffold Hunter. Nat Chem Biol (2009) 1.55
Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguus. Exp Physiol (2012) 1.51
Flow cytometry for high-throughput, high-content screening. Curr Opin Chem Biol (2004) 1.50
Fluorescent genetic barcoding in mammalian cells for enhanced multiplexing capabilities in flow cytometry. Cytometry A (2013) 1.48
QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res (2008) 1.46
Regulation of cell adhesion by affinity and conformational unbending of alpha4beta1 integrin. J Immunol (2007) 1.43
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol (2011) 1.42
Dysregulated FcepsilonRI signaling and altered Fyn and SHIP activities in Lyn-deficient mast cells. J Immunol (2004) 1.40
Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol (2007) 1.37
Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol (2005) 1.37
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res (2010) 1.36
Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl Med Biol (2009) 1.36
The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol (2008) 1.36
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing. Mol Inform (2011) 1.35
Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J Comput Aided Mol Des (2008) 1.32
Novel chemical space exploration via natural products. J Med Chem (2009) 1.27
GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci (2008) 1.25
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J Biomol Screen (2005) 1.22
The development of quantum dot calibration beads and quantitative multicolor bioassays in flow cytometry and microscopy. Anal Biochem (2007) 1.22
Lead-like, drug-like or "Pub-like": how different are they? J Comput Aided Mol Des (2007) 1.21
High-throughput flow cytometry: validation in microvolume bioassays. Cytometry A (2003) 1.21
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem (2011) 1.20
Alpha4beta1 integrin affinity changes govern cell adhesion. J Biol Chem (2003) 1.20
Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol (2012) 1.19
ChemProt-2.0: visual navigation in a disease chemical biology database. Nucleic Acids Res (2012) 1.17
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem (2011) 1.17
Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J Med Chem (2010) 1.16
In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med (2007) 1.16
High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol (2008) 1.14
Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J Biol Chem (2009) 1.14
Rapid evaluation of synthetic and molecular complexity for in silico chemistry. J Chem Inf Model (2005) 1.13
Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol (2009) 1.11
Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. J Neurosci Res (2009) 1.11
Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide. Bioconjug Chem (2009) 1.10
Modulation of bitter taste perception by a small molecule hTAS2R antagonist. Curr Biol (2010) 1.09
Large domain, low-contrast acoustic inverse scattering for ultrasound breast imaging. IEEE Trans Biomed Eng (2010) 1.08
Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal Biochem (2009) 1.08
Ligand-receptor-G-protein molecular assemblies on beads for mechanistic studies and screening by flow cytometry. Mol Pharmacol (2003) 1.07
Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform. Nat Protoc (2006) 1.07
The CARLSBAD database: a confederated database of chemical bioactivities. Database (Oxford) (2013) 1.05
Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol (2013) 1.03
ChemProt: a disease chemical biology database. Nucleic Acids Res (2010) 1.03
Scaffold topologies. 2. Analysis of chemical databases. J Chem Inf Model (2008) 1.02
A quantitative approach for studying IgE-FcepsilonRI aggregation. Mol Immunol (2002) 1.02
N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity. J Biol Chem (2002) 1.02
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther (2007) 1.01
Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation. J Biol Chem (2004) 1.01
Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hypersensitivity via GPR30 in rats. Gastroenterology (2009) 1.00
Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem (2012) 1.00
Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion. BMC Immunol (2008) 0.99
Activation of dioxin response element (DRE)-associated genes by benzo(a)pyrene 3,6-quinone and benzo(a)pyrene 1,6-quinone in MCF-10A human mammary epithelial cells. Toxicol Appl Pharmacol (2007) 0.98
Immobilized stromal cell-derived factor-1alpha triggers rapid VLA-4 affinity increases to stabilize lymphocyte tethers on VCAM-1 and subsequently initiate firm adhesion. J Immunol (2007) 0.98
Emerging trends in the discovery of natural product antibacterials. Curr Opin Pharmacol (2013) 0.97
Relationship between molecular and cellular dissociation rates for VLA-4/VCAM-1 interaction in the absence of shear stress. Biophys J (2004) 0.97
Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay. J Biomol Screen (2009) 0.97
Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry. Anal Biochem (2009) 0.97
Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. Front Immunol (2012) 0.96
Near-simultaneous and real-time detection of multiple analytes in affinity microcolumns. Anal Chem (2004) 0.96